Special Profile & Four Companies Offering Performance Details
June 03 2015 - 7:00AM
InvestorsHub NewsWire
NEW YORK, NY -- June 3, 2015 -- About Small Cap
Traders and Four Brief Reports
Small Cap Traders makes the connection between sophisticated
investors and high quality micro and small cap companies that are
currently undervalued. We are an issuer of reports written by
experienced financial analysts and who provide a straight forward
assessment of a profiled company. They include stocks traded in the
NYSE, NASDAQ, and OTCBB exchanges.
*Special Profile* - Two Clinical Stage Products Lead the Way in a
Promising Pipeline
Actinium Pharmaceuticals, Inc. (NYSE-MKT: ATNM), (“the company”) is
a biopharmaceutical company that develops innovative targeted
payload immunotherapeutics for the treatment of advanced cancers.
The company develops cancer drugs, primarily using its Alpha
Particle Immunotherapy Technology (“APIT) platform. This patented
technology combines monoclonal antibodies (mAB) for targeting
specific types of cells with alpha emitting radioisotopes
(actinium-225 and bismuth-213), and specific beta emitting
radiopharmaceuticals, to precisely target and kill cancerous cells.
The Company’s products are based on patented technology
co-developed with Memorial Sloan Kettering Cancer Center
(MSKCC).
Company Highlights
- -Completed secondary offering, resulting in approximately $18.4
million in proceeds.
-Attained Orphan-Drug Status for Actimab™-A.
-Announced filing for Investigational New Drug meeting with U.S.
FDA to finalize development of Iomab™-B.
-Prepared for Phase 3 Trial of Iomab™-B and Phase 2 Trial of
Actimab™-A by mid-year 2015.
-Merck a leading drug manufacturer holds a large position in
company. (Makin ATNM a Possible Acquisition Target)
For a full analyst report on ATNM that includes a company
overview, market and competition breakdown, recent events, outlook,
valuation, analyst summary and recommendation can be viewed by
using the following link at no cost: http://bit.ly/--ATNM--AnalystReport
Text "SmallCap" to 25827 to receive alerts quicker
4 Four Companies Offering Performance Details:
Sino Agro Food, Inc. (OTCQB: SIAF) is an agriculture technology and
natural food holding company with principal operations in the
People's Republic of China.
The company has released its first quarter financial results. Read
highlights of those financials and a statement by the company CEO
in this report: http://bit.ly/_SIAF_AnalystReport
Fannie Mae (OTCQB: FNMA) is a government-sponsored enterprise that
was chartered by Congress in 1938 to support liquidity, stability
and affordability in the secondary mortgage market, where existing
mortgage-related assets are purchased and sold.
In a recent economic forecast FNMA stated that the 2015 economic
growth forecast was downgraded, but housing is on a better path.
Read the economic highlights in the report you can find at this
link: http://bit.ly/_FNMA_AnalystReport
Amarin Corp., PLC (NASDAQ: AMRN) is a biopharmaceutical company
focused on the commercialization and development of therapeutics to
improve cardiovascular health.
The company has won a summary judgement in court against the FDA
and issued a thorough update of its performance and operations. You
can read about it in the report you will find here: http://bit.ly/_AMRN_AnalystReport
Banro Corp. (NYSE-MKT: BAA) is a Canadian gold mining company
focused on production from the Twangiza mine, which began
commercial production September 1, 2012, and completion of its
second gold mine at Namoya located approximately 200 kilometers
south of the Twangiza gold mine.
BAA has announced a preferred share dividend payable soon. Get the
details of the dividend and the dates involved in the report
offered at this link: http://bit.ly/_BAA_AnalsystReport
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward- looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of mentioned company to be materially different from
the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis
by a 3rd party research analyst. However, we are only human and may
make mistakes. This report was prepared for informational purposes
only. Affiliated parties involved with producing and issuing
this report have not been compensated in any form by the profiled
company or any related party. A full disclaimer can be found
by viewing the full analyst report. We do not engage in high
frequency trading or hold any positions of profiled company. We
have not been compensated in any form for these reports.
For more information and services provided beyond this release
please use contact information provided below. If you notice any
errors or omissions, please notify us below.
A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team,
or wish to learn more about our services, please contact us at
editor@smallcaptraders.com. For any urgent concerns or inquiries
please contact us at editor@smallcaptraders.com.
Source: Small Cap Traders
Contact: editor@smallcaptraders.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2024 to May 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From May 2023 to May 2024